

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <b>KINGSLEY ALFRED D</b>			2. Issuer Name and Ticker or Trading Symbol <b>BIOTIME INC [ BTX ]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <b>See Remarks</b>		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <b>07/31/2017</b>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
<b>150 E. 57TH STREET</b>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
(Street)	<b>NEW YORK</b>	<b>NY</b>	<b>10022</b>					
(City)	(State)	(Zip)						

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares, no par value	07/31/2017		S		150,000 <sup>(1)</sup>	D	\$2.8	5,781,555 <sup>(2)</sup>	D	
Common Shares, no par value								1,143,346	I	By Greenbelt Corp.
Common Shares, no par value								375,351	I	By Greenway Partners, LP

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					
Option to Purchase Common Shares	\$3.15							(3)	06/30/2022	Common Shares	50,000	50,000	D	
Option to Purchase Common Shares	\$2.72							(4)	06/30/2021	Common Shares	50,000	50,000	D	
Option to Purchase Common Shares	\$3.57							(5)	06/30/2020	Common Shares	50,000	50,000	D	
Option to Purchase Common Shares	\$3.11							(6)	06/30/2019	Common Shares	50,000	50,000	D	
Option to Purchase Common Shares	\$4.13							(7)	06/30/2018	Common Shares	50,000	50,000	D	

**Explanation of Responses:**

- The securities were sold in a private transaction. Substantially all of the sale proceeds were invested in AgeX Therapeutics, Inc., a new subsidiary of BioTime.
- Does not include shares that Mr. Kingsley may acquire through the exercise of certain options.
- Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors.
- Became exercisable in four equal quarterly installments after the date of grant on July 1, 2016.
- Became exercisable in four equal quarterly installments after the date of grant on July 1, 2015.
- Became exercisable in four equal quarterly installments after the date of grant on July 1, 2014.
- Became exercisable in four equal quarterly installments after the date of grant on July 1, 2013.

**Remarks:**

/s/Alfred D. Kingsley

08/02/2017

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**